WuXi AppTec Sees Revenue Growth in H1 2025
WuXi AppTec (stock code: 603259.SH / 2359.HK), a leading global provider of R&D and manufacturing services for the pharmaceutical and life sciences industries, has experienced strong financial performance in the first half of 2025. The company reported total revenue of RMB20.80 billion, marking a 20.6% increase compared to the previous year. Notably, revenue from continuing operations soared to RMB20.41 billion, reflecting a year-on-year growth of 24.2%.
Significant Profit Increases
The net profit attributable to the owners of the company rose dramatically, reaching RMB8.56 billion, which is a staggering 101.9% increase year-over-year. This growth translates to diluted earnings per share (EPS) of RMB2.99, also up 106.2% from the prior year.
Adjusted Non-IFRS Results
In terms of adjusted non-IFRS metrics, the net profit attributable to the owners reached RMB6.31 billion, up 44.4% year-over-year. The adjusted non-IFRS diluted EPS was RMB2.20, reflecting a 46.7% increase compared to the same period last year.
Strengthened Backlog and Cash Flow
As of June 30, 2025, the backlog for continuing operations hit a record RMB56.69 billion, up 37.2% year-on-year. The operating cash flow improved significantly, achieving RMB7.07 billion for the first half, which is a 49.1% increase year-over-year.
Business Expansion and Operational Efficiency
WuXi AppTec’s sustained growth is attributed to its integrated Contract Research, Development, and Manufacturing Organization (CRDMO) platform. The company effectively implements strategies such as 'follow the molecule' to drive efficiency and growth. In the first half of 2025 alone, 412 new molecules were introduced into the small molecule Development and Manufacturing (D&M) pipeline, reflecting the continuous expansion of their service offerings.
Global Expansion Success
The company has made significant headway in global expansion and capacity construction. Both Changzhou and Taixing API manufacturing sites successfully passed FDA inspections, a validation of WuXi's commitment to high-quality standards. This momentum is expected to continue as the total reactor volume for small molecule APIs is projected to exceed 4,000kL by the end of 2025.
Sustainability Initiatives
As an innovative partner to the pharmaceutical sector, WuXi AppTec is also dedicated to sustainability. The company has achieved a 'AAA' rating from MSCI for environmental, social, and governance (ESG) initiatives and has set ambitious targets for emissions reductions.
2025 Full-Year Outlook
Despite external uncertainties, WuXi AppTec has raised its full-year guidance. The company anticipates that revenue from continuing operations will experience double-digit growth, with a revised growth rate of 13–17%. Overall, the total revenue forecast for the year is pegged between RMB42.5 billion and RMB43.5 billion, showcasing confidence in its strategic direction and market position.
Shareholder Commitments
The company remains committed to delivering value to its shareholders. In H1 2025, WuXi AppTec distributed a total of RMB3.84 billion in cash dividends, showcasing its commitment to rewarding investors. Further, the board has approved an interim dividend plan for RMB3.50 per share, reinforcing its strategic focus on shareholder returns.
Frequently Asked Questions
What financial growth did WuXi AppTec achieve in H1 2025?
WuXi AppTec reported a total revenue growth of 20.6% year-on-year, reaching RMB20.80 billion, with a net profit increase of 101.9% to RMB8.56 billion.
How did the company perform in terms of profit margins?
The adjusted non-IFRS net profit was RMB6.31 billion, a 44.4% increase, with an adjusted diluted EPS of RMB2.20, up 46.7% year-over-year.
What is the significance of WuXi AppTec's backlog?
The backlog for continuing operations reached a record RMB56.69 billion, indicating strong future revenue potential and operational demand.
How much cash flow did the company generate?
The operating cash flow for the first half of 2025 was RMB7.07 billion, representing a 49.1% increase compared to the previous year.
What are WuXi AppTec's growth expectations for 2025?
The company expects total revenue for 2025 to be between RMB42.5 billion and RMB43.5 billion, with continuing operations projected to grow at 13–17% year-on-year.
